

Supplementary Table S1: Characteristics of the CLL patients								
Patient no.	Rai stage	B2M, mg/L	IgVh mutation	ZAP-70+	No. of prior treatment	Fludarabine-resistant	Percentage TP53 del	Percentage ATM del
Samples used in Table 1								
1	IV	6.3	Unmutated	+	1	Yes	0	0
2	0	2.9	Unmutated	+	0	NT	0	0
3	II	7.9	Unmutated	+	0	NT	0	0
4	III	2.9	Mutated	NA	0	NT	0	0
5	IV	4.5	Unmutated	-	6	Yes	NA	NA
6	0	1.7	Mutated	-	0	NT	0	0
7	I	1.6	NA	-	0	NT	0	0
8	I	3.7	Unmutated	+	0	NT	0	61
9	IV	1.8	Mutated	-	0	NT	0	0
10	II	2.2	Unmutated	+	0	NT	0	0
11	III	3	Unmutated	+	0	NT	0	94
12	IV	6.8	Unmutated	-	0	NT	0	0
13	I	3.2	Unmutated	+	1	NT	NA	NA
14	0	4	Mutated	-	0	NT	18.5	0
15	0	1.8	Mutated	-	0	NT	0	0
16	I	2.9	Unmutated	-	0	NT	0	0
17	0	NA	Unmutated	NA	4	No	NA	NA
18	0	1.9	Mutated	-	0	NT	0	0
19	I	2.2	Mutated	-	0	NT	0	0
20	I	1.9	Mutated	-	0	NT	31.5	0
Samples used in other experiments								
21	I	4.8	Mutated	-	1	NT	0	0
22	0	2.2	Unmutated	NA	0	NT	0	67
23	I	3.9	Mutated	-	1	NT	0	0
24	IV	3.4	Mutated	-	0	NT	0	0
25	IV	3.5	Unmutated	+	0	NT	0	0
26	IV	3.3	Mutated	-	5	No	25.5	0
27	0	1.3	Mutated	-	0	NT	0	0
28	II	NA	Unmutated	+	2	No	74.5	0
29	IV	3	Mutated	-	0	NT	NA	NA
30	0	2.6	Unmutated	+	1	No	0	Loss by CGH
31	0	1.7	Mutated	-	0	NT	0	0
32	II	NA	Unmutated	+	0	NT	NA	NA
33	0	2.2	Mutated	-	0	NT	0	0
34	I	3.2	Unmutated	-	0	NT	0	0

35	I	2.6	Mutated	-	0	NT	0	0
36	0	3.7	Unmutated	+	0	NT	0	0
37	I	3.9	Unmutated	+	2	No	NA	NA
38	0	1.8	Mutated	-	0	NT	0	0
49	0	3.3	Unmutated	-	0	NT	92	0
40	I	2.5	NA	+	0	NT	0	0
41	0	2.7	Mutated	-	0	NT	NA	NA
42	I	2.6	Mutated	-	0	NT	0	0
43	I	2.7	Mutated	-	0	NT	0	0
45	0	2.7	Mutated	-	0	NT	0	0
46	I	3.6	Unmutated	+	0	NT	0	0
47	I	3.5	NA	NA	0	NT	NA	NA
48	I	3.6	Unmutated	+	0	NT	19	0
49	II	NA	Mutated	-	0	NT	0	0